微信小陈
微信小章
产品简介
购买须知
| 产品名称： | FAK+/+ |
|---|---|
| 商品货号： | TS212179 |
| Organism： | Mus musculus, mouse |
| Tissue： | embryo |
| Cell Type： | fibroblast |
| Product Format： | frozen |
| Morphology： | fibroblast |
| Culture Properties： | adherent |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Age： | 8 days gestation |
| Applications： | The FAK+/+ cell line (TS212179) was derived in 1995 from an E8.0 day old mouse embryo that had null mutations only in the p53 gene but not in the FAK gene. It can be used as a control for the FAK-null (ATCC CRL-2644) cell line. The FAK-null (ATCC CRL-2644) cell line was derived from an E8.0 day old mouse embryo that had null mutations in both the nonreceptor protein tyrosine kinase FAK (focal adhesion kinase) gene and the p53 gene. The embryos from which the cell lines were derived were littermates obtained by crossing FAK+/- p53-/- female and FAK+/- p53-/- male. Expression of the FAK-related protein-tyrosine kinase, Pyk2, is elevated in FAK-/- p53-/- fibroblasts compared with FAK+/+ p53-/- cells. |
| Derivation： | The FAK+/+ cell line (TS212179) was derived in 1995 from an E8.0 day old mouse embryo that had null mutations only in the p53 gene but not in the FAK gene. Therefore the cells are genetically FAK+/+ p53-/-. The FAK-null (ATCC CRL-2644) cell line was derived from an E8.0 day old mouse embryo that had null mutations in both the nonreceptor protein tyrosine kinase FAK (focal adhesion kinase) gene and the p53 gene. The embryos from which the cell lines were derived were littermates obtained by crossing FAK+/- p53-/- female and FAK+/- p53-/- male. |
| Clinical Data： | The embryos from which the cell lines were derived were littermates obtained by crossing FAK+/- p53-/- female and FAK+/- p53-/- male. |
| Oncogene： | p53 - |
| Genes Expressed： | p53 - |
| Comments： | The FAK+/+ cell line (TS212179) was derived in 1995 from an E8.0 day old mouse embryo that had null mutations only in the p53 gene but not in the FAK gene. Therefore the cells are genetically FAK+/+ p53-/-. It can be used as a control for the FAK-null (ATCC CRL-2644) cell line. The FAK-null (ATCC CRL-2644) cell line was derived from an E8.0 day old mouse embryo that had null mutations in both the nonreceptor protein tyrosine kinase FAK (focal adhesion kinase) gene and the p53 gene. Therefore, the cells are genetically FAK-/- p53-/-. The embryos from which the cell lines were derived were littermates obtained by crossing FAK+/- p53-/- female and FAK+/- p53-/- male. Expression of the FAK-related protein-tyrosine kinase, Pyk2, is elevated in FAK-/- p53-/- fibroblasts compared with FAK+/+ p53-/- cells. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. |
| Cryopreservation： | culture medium 95%; DMSO, 5% |
| Culture Conditions： | Temperature: 37.0°C |
| Population Doubling Time： | 12 hrs |
| Name of Depositor： | D Ilic |
| Deposited As： | mouse |
| References： | Ilic D, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377: 539-544, 1995. PubMed: 7566154 Sieg DJ, et al. Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J. 17: 5933-5947, 1998. PubMed: 9774338 |